Protein expression of KIT, BRAF, GNA11, GNAQ and RASSF1 in feline diffuse iris melanomas
- PMID: 31239162
- DOI: 10.1016/j.tvjl.2019.04.008
Protein expression of KIT, BRAF, GNA11, GNAQ and RASSF1 in feline diffuse iris melanomas
Abstract
Feline iris melanoma, the most common feline intraocular tumour, has a reported metastatic rate of 19-63%. However, there is a lack of knowledge about its molecular biology. Previous studies have reported that feline iris melanomas do not harbour mutations comparable to common mutations found in their human counterpart. Nevertheless, there are differences in the gene expression patterns. The aim of this study was to investigate the protein expression of B-RAF oncogene serine/threonine kinase (BRAF), G protein subunit alpha q (GNAQ) and 11 (GNA11), KIT proto-oncogene receptor tyrosine kinase (KIT), and Ras association family member 1 (RASSF1) in feline iris melanomas. Fifty-seven formalin-fixed paraffin embedded (FFPE) iris melanomas and 25 FFPE eyes without ocular abnormalities were stained with antibodies against the respective proteins using immunofluorescence. Averaged pixel intensities/μm2 and percentage of stained area from total tissue area were measured and the results were compared. Compared to the control group, iris melanomas showed overexpression of BRAF, GNAQ, GNA11 and KIT. The higher expression of BRAF, GNAQ, GNA11 and KIT in feline iris melanomas suggest that these proteins may play a key role in the development of feline iris melanomas and KIT may present a possible target for future therapies in cats with feline iris melanomas.
Keywords: Expression; Feline iris melanoma; Immunohistochemistry; Oncogene; Protein.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Similar articles
-
Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris Melanoma.Invest Ophthalmol Vis Sci. 2017 Jul 1;58(9):3464-3470. doi: 10.1167/iovs.17-21838. Invest Ophthalmol Vis Sci. 2017. PMID: 28700778
-
Mutation analysis and gene expression profiling of ocular melanomas in cats.Vet Comp Oncol. 2017 Dec;15(4):1403-1416. doi: 10.1111/vco.12285. Epub 2017 Jan 11. Vet Comp Oncol. 2017. PMID: 28074614
-
Mutation scanning of BRAF, NRAS, KIT, and GNAQ/GNA11 in oral mucosal melanoma: a study of 57 cases.J Oral Pathol Med. 2016 Apr;45(4):295-301. doi: 10.1111/jop.12358. Epub 2015 Sep 24. J Oral Pathol Med. 2016. PMID: 26399561
-
Melanoma.Nat Rev Dis Primers. 2015 Apr 23;1:15003. doi: 10.1038/nrdp.2015.3. Nat Rev Dis Primers. 2015. PMID: 27188223 Review.
-
Treatment implications of the emerging molecular classification system for melanoma.Lancet Oncol. 2011 Sep;12(9):913-22. doi: 10.1016/S1470-2045(10)70274-6. Epub 2011 Feb 23. Lancet Oncol. 2011. PMID: 21349766 Review.
Cited by
-
Current Therapeutics and Future Perspectives to Ocular Melanocytic Neoplasms in Dogs and Cats.Bioengineering (Basel). 2021 Dec 20;8(12):225. doi: 10.3390/bioengineering8120225. Bioengineering (Basel). 2021. PMID: 34940378 Free PMC article. Review.
-
Exploring the Epidemiology of Melanocytic Tumors in Canine and Feline Populations: A Comprehensive Analysis of Diagnostic Records from a Single Pathology Institution in Italy.Vet Sci. 2024 Sep 14;11(9):435. doi: 10.3390/vetsci11090435. Vet Sci. 2024. PMID: 39330814 Free PMC article.
-
Feline Uveal Melanoma Review: Our Current Understanding and Recent Research Advances.Vet Sci. 2022 Jan 26;9(2):46. doi: 10.3390/vetsci9020046. Vet Sci. 2022. PMID: 35202299 Free PMC article. Review.
-
A Scoping Review on Tyrosine Kinase Inhibitors in Cats: Current Evidence and Future Directions.Animals (Basel). 2023 Sep 29;13(19):3059. doi: 10.3390/ani13193059. Animals (Basel). 2023. PMID: 37835664 Free PMC article.
-
Clinical Use of Molecular Biomarkers in Canine and Feline Oncology: Current and Future.Vet Sci. 2024 May 2;11(5):199. doi: 10.3390/vetsci11050199. Vet Sci. 2024. PMID: 38787171 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous